Description:

E5103 Disease and Vital Status Form NCT00433511 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=22AFE3B9-AE28-56F9-E044-0003BA3F9857

Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=22AFE3B9-AE28-56F9-E044-0003BA3F9857
Keywords:
  1. 8/26/12 8/26/12 -
  2. 1/8/15 1/8/15 - Martin Dugas
  3. 6/8/15 6/8/15 -
Uploaded on:

June 8, 2015

DOI:
To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

E5103 Disease and Vital Status Form NCT00433511

Instructions: After patient is off treatment, complete this form for each required follow-up report period (see forms submission schedule). Submit original to the ECOG Coordinating Center; Keep a copy for your files.

ECOG clinical trial administrative data
Off Treatment
Off Treatment Report Period (since registration)
Data amendment
Breast: Vital Status
Patient's Vital Status (*IMPORTANT: As soon as a grade 5 adverse event is reported, it is necessary to submit ALL outstanding data in addition to the adverse event form and AdEERS report.)
Primary Cause of Death (if applicable)
Section II - Reporting Period
Section Iii - New Primary Cancers
Has a new primary cancer or MDS been diagnosed that has not been previously reported?
Notice Of First Distance Recurrence
Was first distant recurrence previously reported
Section V - Disease Follow-up Status
Has the patient had a documented clinical assessment for this cancer?
Method of Evaluation
Result
Iib - Local-regional Recurrence
Has the patient been diagnosed with first local-regional recurrence (since submission of the last follow-up form)
Axilla (Sites of local recurrence code all; all sites refer to the same side as the original primary 1=no, 2=yes)
Axillary Node(s)
Infraclavicular Node(s)
Internal mammary node
Ipsilateral Breast
Supraclavicular Node(s)
Basis of Diagnosis
Iic - Distance Recurrence
Has the patient been diagnosed with first distant recurrence/progression? (since submission of the last follow-up form)
Section Iv - Treatment
Hormonal therapy (given this reporting period)
Did patient switch type of hormonal therapy during this report period (If yes:)
Specify new type of adjuvant hormonal therapy administered (If yes:)
Adjuvant Hormonal Therapy Administered Type (If no: - Initial)
Is hormonal therapy continuing
Did patient receive Ovarian Function Suppression (OFS) during this follow-up period?
Specify type (If yes:)
Is LHRH agonist continuing from a previous reporting period (If LHRH agonist:)
Section Viii - Non-protocol Therapy Prior To Recurrence
Has the patient received any non-protocol cancer therapy prior to first recurrence (not previously reported)
Footer Module

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial